SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Doubts over glycaemic lowering treatments
Thurs November 16th - Treatments aimed at minimising glycaemic levels in patients with type 2 diabetes may increase mortality risk, according to a major UK study. More
RECENT COMMENTS
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...
On 11/02/2016 Gary thomson wrote:
Can't wait for this to be available in constant pa... on Mood drug may tackle chronic p...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

Benefits of early HIV treatment

Thursday January 17th, 2013

Sustained treatment of HIV infection early on in the disease can have long term benefits for patients, researchers reported last night.

The British led study tested the benefits of treating patients with anti-viral drugs for 48 weeks as early as possible in the course of infection.

Research was undertaken in countries such as Australia, South Africa, Brazil, Spain, Italy and Ireland.

It involved some 366 adults over five years.

Reporting in the New England Journal of Medicine, the researchers say the treatment reduced viral levels in the blood for up to 60 weeks after treatment was stopped.

It also delayed the need for long-term treatment - although the delay was only a little longer than the 48 weeks that patients had already spent on drugs.

Researcher Dr Sarah Fidler, from Imperial College London, said: "These results are promising and suggest that a year-long course of treatment for people recently infected with HIV may have some benefit on both the immune system as well as helping control the virus.

"The treatment also reduces the amount of virus in the body for some time after the patient has stopped taking the medication. This could be very important for helping reduce the risk of passing on the virus to a sexual partner."

Professor Gita Ramjee, director of the South African Medical Research Council's HIV Prevention Research Unit, said: "We now need to weigh up whether the benefits offered by early intervention are outweighed by the strategic and financial challenges such a change in policy would incur, particularly in resource-poor settings such as Africa, although this may be where the most benefits are seen in terms of TB rates."

SPARTAC Trial Investigators. The effect of short-course antiretroviral therapy in primary HIV infection: final results from SPARTAC, an international randomized controlled trial. NEJM; 17 Jan 2013.

Tags: Africa | Europe | Flu & Viruses | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES